• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Porcine parvovirus vaccine demonstrates promise in clinical study

February 28, 2023

The platform technology, in which specific antigens are expressed by genetically modified yeast cells, was developed by the research and development team of Germany-based serYmun Yeast GmbH.

A controlled target animal study has demonstrated the protective immunization of pigs against porcine parvovirus (PPV). According to serYmun Yeast GmbH, an animal health vaccine development company based in Germany, the study’s findings are a breakthrough in the development of the first pig vaccine candidate against PPV.1

The common disease can result in reproductive failure and is endemic is most swine herds. It is often resistant to environmental degradation and many disinfectants, while persisting for at least 4 months on contaminated premises.2

Following 2 intramuscular injections of serYmun’s proprietary vaccine candidate, the treated group showed high titers of serum neutralizing antibodies 7 days after vaccination, and a second peak after booster immunization on day 21. In a positive control group, a recently launched commercial product of an industry-leading animal health company showed antibody titers at a comparable level. The negative control group did not show seroconversion.1

The vaccinated animals did not show any adverse clinical effects, which indicates safety of the vaccine, according to serYmun.1 “I am extremely happy and proud that our team has been successful in developing this vaccine and its basic platform technology in only 4 years”, said Wilhelm von Trott zu Solz, DVM, cofounder and CEO of serYmun Yeast GmbH, in a compnay release. “This encourages us to start the registration process to launch our PPV and other vaccines."

Advertisement

The yeast-based platform technology, in which specific antigens are expressed by genetically modified yeast cells, was developed by the research and development team of serYmun.1 “Based on our technology, our vaccines will benefit animals, farmers, and veterinarians enormously. Our vaccine platform allows to develop safe and polyvalent vaccines in a record time and at comparably very low costs,” said von Trott zu Solz, in the release.

serYmun Yeast will be present the findings of the study at the Animal Health, Nutrition and Technology Innovation Conference in London, March 5-8, 2023.1

Reference

  1. serYmun Yeast announces preclinical safety and efficacy data for their yeast-based vaccine against porcine parvovirus (PPV). News release. serYmun Yeast. February 27, 2023. Accessed February 28, 2023. https://www.b3cnewswire.com/202302272446/serymun-yeast-announces-preclinical-safety-and-efficacy-data-for-their-yeast-based-vaccine-against-porcine-parvovirus-ppv.html
  2. Swine manual: Parovirus. Iowa State University College of Veterinary Medicine. Accessed February 28, 2023. https://vetmed.iastate.edu/vdpam/FSVD/swine/index-diseases/parvovirus

Related Content:

Exotic Animal MedicineInfectious DiseasesPharmacy
Oldest tortoise at Houston Zoo becomes father to 3 hatchlings
Oldest tortoise at Houston Zoo becomes father to 3 hatchlings
Senior penguins receive revolutionary cataract surgery
Senior penguins receive revolutionary cataract surgery
Veterinarian with a love for wildlife photography
Veterinarian with a love for wildlife photography

Advertisement

Latest News

3 Must-sees for Women's History Month

News wrap-up: This week’s headlines, plus Embrace announces its top Irish pet names

Oldest tortoise at Houston Zoo becomes father to 3 hatchlings

Veterinary tech students awarded national scholarship

View More Latest News
Advertisement